[A22-71] Pembrolizumab (renal cell carcinoma) – Benefit assessment according to § 35a SGB V
Last updated 19.01.2023
Commission awarded on 19.07.2022 by the Federal Joint Committee (G-BA).
Adjuvant treatment of adult patients with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
Hint of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.